Brineura™ (Cerliponase Alfa)

COVERAGE RATIONALE

Brineura is proven and medically necessary for slowing the loss of ambulation in symptomatic pediatric patients with Late Infantile Neuronal Ceroid Lipofuscinosis (LINCL) type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency when all of the following criteria are met:

I. For initial therapy, all of the following:
   A. One of the following:
      1. Diagnosis of Late Infantile Neuronal Ceroid Lipofuscinosis type 2 (CLN2) by a neurologist with expertise in the diagnosis of CLN2
      2. Diagnosis of Late Infantile Neuronal Ceroid Lipofuscinosis type 2 (CLN2) by a physician in consultation with a neurologist with expertise in the diagnosis of CLN2
   and
   B. Patient is age 3 years or older; and
   C. All of the following scores on the Clinical Scoring System for LINCL:
      1. Combined score of 3 to 6 in the motor and language domains
      2. Score of at least 1 in the motor domain
      3. Score of at least 1 in the language domain
   and
   D. One of the following:
      1. Brineura is prescribed by a neurologist with expertise in the treatment of CLN2
      2. Brineura is prescribed by a physician in consultation with a neurologist with expertise in the treatment of CLN2
   and
   E. Brineura is to be administered intraventricularly by, or under the direction of, healthcare professionals experienced in performing intraventricular infusions via an intracerebroventricular catheter; and
   F. Dosing is in accordance with the United States Food and Drug Administration approved labeling: 300 mg administered once every other week as an intraventricular infusion; and
   G. Initial authorization will be for no more than 6 months.

II. For continuation therapy, all of the following:
   A. One of the following:
      1. Diagnosis of Late Infantile Neuronal Ceroid Lipofuscinosis type 2 (CLN2) by a neurologist with expertise in the diagnosis of CLN2
      2. Diagnosis of Late Infantile Neuronal Ceroid Lipofuscinosis type 2 (CLN2) by a physician in consultation with a neurologist with expertise in the diagnosis of CLN2
   and
   B. Patient is age 3 years or older; and

See Benefit Considerations

Related Policies
None
C. Patient has a score of 1 or higher in the motor domain of the Clinical Scoring System for LINCL\(^4\); and

D. **One** of the following:
   1. Brineura is prescribed by a neurologist with expertise in the treatment of CLN2
   2. Brineura is prescribed by a physician in consultation with a neurologist with expertise in the treatment of CLN2

and

E. Brineura is to be administered intraventricularly by, or under the direction of, healthcare professionals experienced in performing intraventricular infusions via an intracerebroventricular catheter; and

F. Dosing is in accordance with the United States Food and Drug Administration approved labeling: 300 mg administered once every other week as an intraventricular infusion; and

G. Reauthorization will be for no more than 6 months.

**Brineura (cerliponase alfa) is unproven and not medically necessary for other forms of Neuronal Ceroid Lipofuscinosis.**

**U.S. FOOD AND DRUG ADMINISTRATION (FDA)**

Brineura (cerliponase alfa) is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency\(^1\).

**BACKGROUND**

Neuronal ceroid lipofuscinosis type 2 (CLN2), is a neurodegenerative lysosomal storage disorder caused by deficient activity of the enzyme tripeptidyl peptidase. CLN2 is autosomal recessive and pediatric-onset, and is characterized by seizures, language delay, movement disorders, motor deterioration, dementia, blindness, and early death\(^2,3\). A Clinical Scoring System for Late Infantile Neuronal Ceroid Lipofuscinoses has been developed as a method for quantitative description of clinical courses over time\(^4\).

**APPLICABLE CODES**

The following list(s) of procedure and/or diagnosis codes is provided for reference purposes only and may not be all inclusive. Listing of a code in this policy does not imply that the service described by the code is a covered or non-covered health service. Benefit coverage for health services is determined by the member specific benefit plan document and applicable laws that may require coverage for a specific service. The inclusion of a code does not imply any right to reimbursement or guarantee claim payment. Other Policies and Coverage Determination Guidelines may apply.

<table>
<thead>
<tr>
<th>HCPCS Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J0567</td>
<td>Injection, cerliponase alfa, 1 mg</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ICD-10 Diagnosis Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>E75.4</td>
<td>Neuronal ceroid lipofuscinosis</td>
</tr>
</tbody>
</table>

**BENEFIT CONSIDERATIONS**

Some Certificates of Coverage allow for coverage of experimental/investigational/unproven treatments for life-threatening illnesses when certain conditions are met. The member specific benefit plan document must be consulted to make coverage decisions for this service. Some states mandate benefit coverage for off-label use of medications for some diagnoses or under some circumstances when certain conditions are met. Where such mandates apply, they supersede language in the benefit document or in the medical or drug policy. Benefit coverage for an otherwise unproven service for the treatment of serious rare diseases may occur when certain conditions are met. See the Policy and Procedure addressing the treatment of serious rare diseases.

**CLINICAL EVIDENCE**

**Proven**

*Ceroid Lipofuscinosis Type 2 (CLN2) / Tripeptidyl Peptidase 1 (TPP1) Deficiency*

Cerliponase alfa is indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.\(^1\)*
In a multicenter, open-label study, Schulz A. et al evaluated the effect of intraventricular infusion of cerliponase alfa every 2 weeks in pediatric patients with CLN2. The primary outcome compared the duration until a 2-point decline in the score on the motor and language domains of the CLN2 Clinical Rating Scale in study patients to the rate of decline in 42 historical controls. In addition, the rate of decline in the motor-language score was compared between the two groups. Of the 24 patients enrolled, 23 constituted the efficacy population. The median time until a 2-point decline in the motor-language score was not reached for treated patients and was 345 days for historical controls. The mean (±SD) unadjusted rate of decline in the motor-language score per 48-week period was 0.27±0.35 points in treated patients and 2.12±0.98 points in 42 historical controls (mean difference, 1.85; P<0.001). Common adverse events included convulsions, pyrexia, vomiting, hypersensitivity reactions, and failure of the intraventricular device. Infections developed in the intraventricular device for administration in 2 patients, required antibiotic treatment and device replacement. The authors conclude that intraventricular infusion of cerliponase alfa in patients with CLN2 disease resulted in less decline in motor and language function than that in historical controls.

Clinical evidence for the safety and efficacy of cerliponase alfa for the treatment of late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) was demonstrated in a prospective Phase 1/2 Open-Label Dose-Escalation Study and Extension. The objective of the study was to evaluate the safety and tolerability of cerliponase alfa administered to patients with CLN2 disease by intraventricular administration. There were 5 study centers involved. Patients were treated with intraventricular infusion of cerliponase alfa with doses ranging from 30 to 300 mg every 14 days in the dose escalation study and were maintained at 300 mg every 14 days in the extension study. The primary endpoint was response rate, defined as the absence of an unreversed two-point decline or score of zero in the CLN2 score at 48 weeks. 24 patients were enrolled, with 23 patients completing the study. By motor/language CLN2 scores measured from baseline, 87% (20/23) of treated patients responded to treatment, defined as an absence of an unreversed two-point decline or score of zero by Week 48, compared to an expected response rate of 50% (P-value=0.0002). Sixty-five percent of treated patients experienced no progression in their CLN2 score. Of all points lost, approximately 80% occurred within four months of treatment initiation. The proportion of patients with a response to treatment was 87% at Week 48 and 63% at Week 96.

CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS)

Medicare does not have a National Coverage Determination (NCD) that specifically addresses Brineura® (cerliponase alfa). Local Coverage Determinations (LCDs) do not exist at this time.

Medicare may cover outpatient (Part B) drugs that are furnished “incident to” a physician’s service provided that the drugs are not usually self-administered by the patients who take them. See the Medicare Benefit Policy Manual, Chapter 15, 650 - Drugs and Biologicals. (Accessed May 8, 2018)

REFERENCES

5. AMCP Dossier for Brineura™ (cerliponase alfa), BioMarin Pharmaceutical, May 2017.

POLICY HISTORY/REVISION INFORMATION

<table>
<thead>
<tr>
<th>Date</th>
<th>Action/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>03/01/2019</td>
<td>Reorganized policy template; simplified and relocated Instructions for Use and Benefit Considerations section. Archived previous policy version 2019D0065D.</td>
</tr>
<tr>
<td>01/01/2019</td>
<td>Updated list of applicable HCPCS codes to reflect annual code edits; replaced C9014 and J3590 with J0567. Policy 2018D0065C archived.</td>
</tr>
<tr>
<td>07/01/2018</td>
<td>Annual Review. No changes to coverage rationale. Updated clinical evidence and references. Approved by the National Pharmacy and Therapeutics Committee 06/20/2018. Policy version 2018D0065B archived.</td>
</tr>
<tr>
<td>01/01/2018</td>
<td>Updated list of applicable HCPCS codes to reflect annual code edits; added C9014. Archived previous policy version 2017D0065A.</td>
</tr>
</tbody>
</table>
INSTRUCTIONS FOR USE

This Medical Benefit Drug Policy provides assistance in interpreting UnitedHealthcare benefit plans. When deciding coverage, the member specific benefit plan document must be referenced as the terms of the member specific benefit plan may differ from the standard benefit plan. In the event of a conflict, the member specific benefit plan document governs. Before using this policy, please check the member specific benefit plan document and any applicable federal or state mandates. UnitedHealthcare reserves the right to modify its Policies and Guidelines as necessary. This Medical Benefit Drug Policy is provided for informational purposes. It does not constitute medical advice.

This Medical Benefit Drug Policy may also be applied to Medicare Advantage plans in certain instances. In the absence of a Medicare National Coverage Determination (NCD), Local Coverage Determination (LCD), or other Medicare coverage guidance, CMS allows a Medicare Advantage Organization (MAO) to create its own coverage determinations, using objective evidence-based rationale relying on authoritative evidence (Medicare IOM Pub. No. 100-16, Ch. 4, §90.5).

UnitedHealthcare may also use tools developed by third parties, such as the MCG™ Care Guidelines, to assist in administering health benefits. UnitedHealthcare Drug Policies are intended to be used in connection with the independent professional medical judgment of a qualified health care provider and do not constitute the practice of medicine or medical advice.